Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00125372 · ClinicalTrials.gov registry record · NA
Study of Tarceva and Targretin in Stage I-II Lung Cancer
A NA study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT00125372 is a NA study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT00125372, a NA study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.
Interventions
- DRUG erlotinib (Tarceva) and bexarotene (Targretin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-12 |
| Est. Completion | 2010-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00125372
The ClinicalTrials.gov registry entry for NCT00125372 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which erlotinib (Tarceva) and bexarotene (Targretin) is the first listed.
NCT00125372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00125372 about?
NCT00125372 is a clinical study titled "Study of Tarceva and Targretin in Stage I-II Lung Cancer". The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the treatment of cutaneous T-cel...
What is the current status of trial NCT00125372?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2005-12. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00125372?
The interventions under investigation include: erlotinib (Tarceva) and bexarotene (Targretin) (DRUG).
Who is sponsoring clinical trial NCT00125372?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.